Ruth Ruddle

1.8k citations

23 papers · 652 indexed · h-index 12

Cancer Research
- Cancer, Hypoxia, and Metabolism 6
Molecular Biology
- PI3K/AKT/mTOR signaling in cancer 6
- Biochemical and Molecular Research 4
Oncology
- Cancer Treatment and Pharmacology 3
- Colorectal Cancer Treatments and Studies 2
Cell Biology
Pathology and Forensic Medicine
- Cancer Mechanisms and Therapy 2
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 3
- Renal cell carcinoma treatment 2

Co-authors: Florence I. Raynaud Paul Workman Suzanne A. Eccles Melanie Valenti Michelle D. Garrett Alexis de Haven Brandon Ian Collins John Caldwell
Cited by: Cancer Research Molecular Biology Oncology
Journals: Journal of Clinical Oncology (4 papers)Molecular Cancer Therapeutics (3 papers)Cancer Research (3 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

Ruth Ruddle

21 papers receiving 646 citations

Peers

Countries citing papers authored by Ruth Ruddle

Since Specialization

Citations

This map shows the geographic impact of Ruth Ruddle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Ruddle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Ruddle more than expected).

Fields of papers citing papers by Ruth Ruddle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth Ruddle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Ruddle. The network helps show where Ruth Ruddle may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ruth Ruddle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ruth Ruddle Line = papers co-authored together Ruth Ruddle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	85P: Phase I results from the phase I/II POTENT trial of tepotinib and pembrolizumab in non-small cell lung cancer (NSCLC) Journal of Thoracic Oncology ·文吉野,姚晓芳,Bruna Costa Lemos Silva,Athanasios Zachariou,Ji-Sung Kim,Sudhir Venkatesan,Hiteshree Kantharia,Ernest Hetenyi,Xiaolin Hu,Ruth Ruddle,Christina Yap,Viraj R. Adduru,Шкиль Николай Николаевич,Juanita Lopez,Johann S. de Bono,Gulchekhra Abdullaeva,Udai Banerji,Lamine Savané,Charlotte Lindsay,Anna Minchom	2025	0
2	Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial Cancer Research ·Simon Pacey,Dan Wang,Simon Rodney,Canales Betanco,Ruth Ruddle,Усачев А.В.,Karen E. Swales,Robert te Poele,Paul Workman,Gomzikova EA,S.J. Kim,Enrique Poradosu,Shay Shemesh,Udai Banerji	2024	1
3	Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors Molecular Cancer Therapeutics ·Udai Banerji,Simon Pacey,Amaka Yves-Ann Ezeuko,Simon Rodney,Canales Betanco,Giovanni Codacci-Pisanelli,子簃,Florence I. Raynaud,Ruth Ruddle,Karen E. Swales,Усачев А.В.,Shay Shemesh,Gomzikova EA,S.J. Kim,Justin L. Hay,Robin Bliss,Enrique Poradosu,Paul Workman	2023	1
4	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes Molecular Cancer Therapeutics ·Elizabeth A. Coker,Adam Stewart,Buğra Özer,Anna Minchom,Lisa Pickard,Ruth Ruddle,Suzanne Carreira,Sanjay Popat,Mary O’Brien,Florence I. Raynaud,Johann S. de Bono,Bissan Al‐Lazikani,Udai Banerji	2022	8
5	First-in-Human Study of AT13148, a Dual ROCK-AKT Inhibitor in Patients with Solid Tumors Clinical Cancer Research ·Aakanksha,Rajiv Kumar,Dionysis Papadatos-Pastos,Joaquı́n Mateo,Jessica Brown,Alvaro Ingles Garces,Ruth Ruddle,Shaun Decordova,Simone Jueliger,Roberta Ferraldeschi,Óscar Maiques,Victoria Sanz‐Moreno,Paul S. Jones,Stephanie Traub,Gavin Halbert,Ralf Kieser,Karen E. Swales,Florence I. Raynaud,Michelle D. Garrett,Udai Banerji	2020	52
6	Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation Metabolomics ·Ákos Pál,Yasmin J. Asad,Ruth Ruddle,Alan T. Henley,Karen E. Swales,Shaun Decordova,Suzanne A. Eccles,Ian Collins,Michelle D. Garrett,Johann S. de Bono,Udai Banerji,Florence I. Raynaud	2020	3
7	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors. Journal of Clinical Oncology ·Udai Banerji,Alvaro Ingles Garces,Vasiliki Michalarea,Ruth Ruddle,Florence I. Raynaud,Ruth Riisnaes,Daniel Nava Rodrigues,Nina Tunariu,Joanna C. Porter,Sarah Ward,Mona Parmar,Alison Turner,D Manavipour,Emma Hall,Emma Dean,Bristi Basu,Angela George,Stan B. Kaye,Susana Banerjee,Johann S. de Bono	2017	12
8	p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance Cancer Research ·Orli Yogev,Karen Barker,Marieluise Merz,Gilberto S. Almeida,Albert Hallsworth,Laura Smith,Yann Jamin,Ruth Ruddle,Alexander Koers,Hannah Webber,Florence I. Raynaud,Sergey Popov,Chris Jones,Kevin Petrie,Simon P. Robinson,Hector C. Keun,Louis Chesler	2016	32
9	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts) European Journal of Cancer ·Vasiliki Michalarea,José Ramón Antúnez López,David Lorente,Suzanne Carreira,Mohd Shafie B. Rosli,Mona Parmar,Andrea Turner,Emma Hall,Siqintana Xin,Shaun Decordova,Karen E. Swales,Ruth Ruddle,Florence I. Raynaud,Nina Tunariu,TanneeruVenu Gopal Rao,L. Rhoda Molife,Udai Banerji,Ruth Plummer,Johann S. de Bono,Tami Yap	2015	1
10	TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. Journal of Clinical Oncology ·Desamparados Roda,Han Hsi Wong,Elena Geuna,Saeed Rafii,Ruth Ruddle,Angela Hayes,Karen E. Swales,Sepideh Hamdamian,Andrés Felipe Castañeda López,Nina Tunariu,Alison Turner,Emma Hall,Timothy A. Yap,Susana Banerjee,Mary O’Brien,L. Rhoda Molife,Stan B. Kaye,Johann S. de Bono,Bristi Basu,Udai Banerji	2014	2
11	First-in-human, first-in-class phase 1 study of a novel oral multi-AGC kinase inhibitor AT13148 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology ·Rajiv Kumar,Joaquı́n Mateo,Alan D. Smith,Khurum Khan,Ruth Ruddle,Karen E. Swales,Shaun Decordova,Kwang Yih Mah,Paul S. Jones,Scott Kircher,D Manavipour,Aakanksha,Timothy A. Yap,Florence I. Raynaud,Michelle D. Garrett,Udai Banerji	2014	9
12	Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo Clinical Cancer Research ·Jane Renshaw,Kathryn R. Taylor,Ryan T. Bishop,Melanie Valenti,Alexis de Haven Brandon,Sharon Gowan,Suzanne A. Eccles,Ruth Ruddle,Louise D. Johnson,Florence I. Raynaud,Joanna Selfe,Khin Thway,Torsten Pietsch,Andrew D.J. Pearson,Janet Shipley	2013	110
13	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription Cancer Research ·Kenneth Ewan,Bożena Pająk,Mark Stubbs,E A Davies,Olivier Barbeau,Camilo Quevedo,Hannah Botfield,Rodrigo Young,Ruth Ruddle,Joona Luukka,Alysia Battersby,Florence I. Raynaud,Nicholas D. Allen,Stephen W. Wilson,Branko Latinkic,Paul Workman,Edward McDonald,Julian Blagg,Wynne Aherne,Trevor Dale	2010	86
14	Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930 Molecular Cancer Therapeutics ·Timothy A. Yap,Mike I. Walton,Virginia G Jaquish,Melanie Valenti,Alexis de Haven Brandon,Paul D. Eve,Ruth Ruddle,Simon P. Heaton,Alan T. Henley,Lisa Pickard,Gowri Vijayaraghavan,John Caldwell,Neil T. Thompson,Wynne Aherne,Florence I. Raynaud,Suzanne A. Eccles,Paul Workman,Ian Collins,Michelle D. Garrett	2010	59
15	Discovery of 4-Amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt) Journal of Medicinal Chemistry ·Tatiana McHardy,John Caldwell,Kwai-Ming J. Cheung,Yangjun Qiao,Kevin Taylor,Martin Rowlands,Ruth Ruddle,Alan T. Henley,Alexis de Haven Brandon,Melanie Valenti,Thomas G. Davies,Lynsey Fazal,Lisa C. A. Seavers,Florence I. Raynaud,Suzanne A. Eccles,G. Wynne Aherne,Michelle D. Garrett,Ian Collins	2010	67
16	A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy British Journal of Cancer ·А.Л. МАКСИМОВ,Geoffrey S. Payne,Sayed Nasr Al - Mahboubi,Ruth Ruddle,Nada Alhafez,Florence I. Raynaud,David Eaton,Michael J. Campbell,Bettina Müller,Gavin Halbert,Michaël Tracy,J.P. McNamara,Beatrice Seddon,Martin O. Leach,Paul Workman,Ian Judson	2009	27
17	An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models Cancer Chemotherapy and Pharmacology ·Udai Banerji,L.A. Wori,Swee Y. Sharp,Melanie Valenti,Yasmin J. Asad,Ruth Ruddle,Florence I. Raynaud,Michael I. Walton,Suzanne A. Eccles,Ian Judson,Ann L. Jackman,Paul Workman	2008	30
18	Identification of 4-(4-Aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as Selective Inhibitors of Protein Kinase B through Fragment Elaboration Journal of Medicinal Chemistry ·John Caldwell,Thomas G. Davies,Alastair Donald,Tatiana McHardy,Martin Rowlands,G. Wynne Aherne,Mohamed Sir Elkhatim Hamid,Kevin Taylor,Ruth Ruddle,Florence I. Raynaud,Marcel L. Verdonk,Paul Workman,Michelle D. Garrett,Ian Collins	2008	74
19	The Phosphoinositide-Specific Phospholipase C Inhibitor U73122 (1-(6-((17β-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) Spontaneously Forms Conjugates with Common Components of Cell Culture Medium Drug Metabolism and Disposition ·Nicola E. Wilsher,Shaun Ivan Robertson,Ruth Ruddle,Yvette Newbatt,Wynne Aherne,Peter Sheldrake,Neil P. Jones,Matilda Katan,Suzanne A. Eccles,Florence I. Raynaud	2007	28
20	A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies British Journal of Cancer ·T. Benepal,Ann L. Jackman,L Pyle,Tania Edwards,Anthea Hardcastle,Wynne Aherne,F. Mitchell,Laura K. Simmons,Ruth Ruddle,Florence I. Raynaud,Martin Gore	2005	3

About Ruth Ruddle

Ruth Ruddle is a scholar working on Cancer Research, Biochemistry, Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 23 papers that have together received 652 indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Biochemical and Molecular Research (4 papers), Cancer Treatment and Pharmacology (3 papers), Lung Cancer Treatments and Mutations (3 papers), Cancer Mechanisms and Therapy (2 papers), Renal cell carcinoma treatment (2 papers) and Colorectal Cancer Treatments and Studies (2 papers). The work is most often cited by research in Cancer Research (98 citations), Molecular Biology (409 citations), Oncology (137 citations), Cell Biology (62 citations) and Pathology and Forensic Medicine (66 citations). Ruth Ruddle has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Florence I. Raynaud, Paul Workman, Suzanne A. Eccles, Melanie Valenti, Michelle D. Garrett, Alexis de Haven Brandon, Ian Collins, John Caldwell, Wynne Aherne and Martin Rowlands. Their work appears in journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics, Cancer Research, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact